DailyIQ
Last updated2 minutes ago

DVA·DaVita Inc.

$182.06
+0.28 (+0.15%)
Overnight$182.08+0.02 (+0.01%)
High
$183.70
Open
$182.58
Market Cap
11.60B
52W High
$247.49
Low
$181.69
P. Close
$182.06
P/E
13.69
52W Low
$101.00
Fwd P/E
10.62
DailyIQ Est.
$223.01
Inst. Ownership
69.7%
Short Interest
8.08%
Days to Cover
6.5
Technical Score (1D)
59
BULLISH
News Sentiment
70
BULLISH
DVA is setting up for a potential resolution: NEUTRAL at 59 with mixed momentum on the 1D chart. Sentiment at 70 is diverging from the bullish bias, so confirmation still matters. $189.49 is the line bulls need to clear; $174.91 defines the risk if the attempt stalls. The difference between a breakout and a breakout attempt is follow-through - a close above $189.49 that holds into the next session carries far more weight than an intraday poke through the level. Until that confirmation shows up, $174.91 defines the risk for anyone positioning ahead of the move rather than waiting for it.
LOW TARGET
$165 -9.4%
2 analysts
MEAN TARGET
$220 +20.8%
8 analysts
HIGH TARGET
$270 +48.3%
4 analysts
PRICE RANGE
$165.00 - $270.00
SB / B / H / S / SS
1/6/5/1/1
DAILYIQ EST.
$223.01 (+22.5%)
Sector
Healthcare
Industry
Medical Care Facilities
Exchange
NYQ
Country
United States
Website
Symbol
DVA
Description
DaVita Inc. is a leading provider of kidney dialysis services, primarily serving patients with chronic kidney failure within the United States. The company's core business revolves around operating outpatient dialysis centers where it delivers hemodialysis treatments and related laboratory services. Beyond outpatient care, DaVita offers a comprehensive suite of services, including inpatient and home-based dialysis options, along with integrated care programs designed to manage patient health. The company also supports its operations through clinical laboratories and provides administrative services to dialysis centers. Established in 1994 and headquartered in Denver, Colorado, DaVita has evolved to offer a broad spectrum of kidney care solutions.
Bought (1Y)
0 shares
$0
Sold (1Y)
291,410 shares
$58.8M
Maughan David PaulChief Operating Officer, DKC
Tax Withholding7,501 shares2026-09-22
YALE PHYLLIS R-
Award/Grant278 shares2026-08-15
Arway Pamela M-
Award/Grant278 shares2026-08-15
Schoppert Wendy Lee-
Award/Grant278 shares2026-08-15
Pullin Dennis W-
Award/Grant278 shares2026-08-15
64/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
5.5%
Revenue CAGR
5.4%
Current Ratio
1.29x
Debt / Equity
-15.75x
Return on Equity
-114.7%
Earnings Summary
DaVita Inc. operates outpatient dialysis centers and offers inpatient, home‑based dialysis, laboratory, and administrative services to patients with chronic kidney failure, positioning it as a comprehensive kidney care provider within the medical care facilities sector. In the most recent two quarters, DaVita’s earnings per share rose from $2.24 in Q4 2024 to $2.95 in Q2 2025, while revenue climbed from $3.294 billion to $3.380 billion, reflecting a modest acceleration in top‑line growth; however, Q3 2025 EPS fell to $2.51 despite revenue reaching $3.420 billion, indicating a deceleration in profitability. Historically, the company has delivered consistent revenue growth, with EPS beating estimates in three of the last four quarters, though the Q3 2025 miss suggests volatility in earnings relative to guidance. Recent news highlights a strong market outlook, with analysts projecting a 50.6% YoY earnings increase to $3.78 per share for the current quarter and a full‑year estimate of $14.57 per share, underscoring investor confidence; meanwhile, Berkshire Hathaway’s partial divestiture signals a potential shift in institutional ownership but does not materially alter operational performance.

EPS

EstBeatMiss
$1.70$2.35$3.01$3.67$4.32Q1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.57 - -
Q2'26$3.92$4.02+2.5%
Q1'26$2.33$2.87+23.2%
Q3'25$3.17$2.51-20.9%
Q2'25$2.75$2.95+7.3%
Q1'25$2.02$2.00-1.0%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.5B$3.6BQ1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.5B - -
Q2'26$3.5B$3.6B+0.6%
Q1'26$3.4B$3.4B+1.8%
Q3'25 - $3.4B -
Q2'25 - $3.4B -
Q1'25 - $3.2B -

Market Data

DVA Stock Snapshot

NEUTRAL59/100
$182.08+$0.02 (0.0%)
Market cap
11.60B
P/E ratio
13.7
Day range
$181.69 – $183.70
News sentiment
70/100 · Bullish
Analyst target
$219.86 (+20.7%)
Consensus
Buy · 14 analysts
52-week range+80.3% off low · -26.4% from high
$101.00$247.49
Price $182.08 DailyIQ Est. $223.01

DaVita Inc. is consolidating: price is in the middle of its 52-week range without a decisive push either way. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into DVA?

CHEAP

At today's price, DaVita Inc. needs to grow free cash flow about -8.5% a year for the next 10 years to justify its valuation at a 6.20% cost of capital. Over its actual history it has compounded free cash flow at 8.2% a year, so the market is asking for 16.7 percentage points below its own delivered rate. On that basis DVA looks priced below what its own growth record supports.

Implied FCF growth
-8.5%
Historical FCF CAGR
8.2%
Growth gap
-16.7 pts
Verdict
CHEAP
Discount rate (WACC)
6.20%
Beta
0.55

Behaviour On Record

What DVA's own history says about today's numbers

Realized volatility (21d)
32.9% 74th pct
Below its peak
-25.6%
vs 200-day average
+4.7%
Up days (1y)
53%

DaVita Inc. is currently running 32.9% annualised volatility over the last 21 sessions. Measured against DVA's own 13 years of daily returns rather than a market-wide average, that is the 74th percentile — a little above its own norm, against a typical reading of 24.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

DVA is trading -25.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -27.8%, and the deepest was -46.7% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +4.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 54th percentile — close to the gap it normally carries. Over the past year DVA closed higher on 53% of sessions, and it is currently 3 sessions into a rising streak.

On October specifically: over 13 years of records, DVA finished the month higher 5 of 13 times, with a median return of -8.5% and an average of -5.2%. Its strongest month historically has been November at +7.0% on average, its weakest October at -5.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: DVA has opened more than 2% away from the prior close in 93 of 3,266 sessions (2.8% of the time), with the largest gaps running +8.3% and -7.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against DVA's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of DVA's sector?

DaVita Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for DVA?

CallsPuts

For DaVita Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.25), with at-the-money implied volatility around 58.0%. The options market is pricing roughly a ±4.2% move by that expiry — a range of about $167.84–$182.54.

Put/call ratio (2026-10-16)
0.25
ATM implied volatility
58.0%
Total open interest
14,980
Expected move by 2026-10-16
±4.2% ($167.84–$182.54)

Analyst Rating Changes

Are analysts turning bullish or bearish on DVA?

TD Cowen most recently upgraded DaVita Inc. to Buy on Aug 7, 2026 with a price target of $220 (from $201). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
TD Cowen — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Aug 7, 2026TD CowenUpgradeHold → Buy$201 → $220
Aug 7, 2026Truist SecuritiesMaintainedHold$250 → $215
Aug 5, 2026BarclaysMaintainedEqual-Weight$218 → $224
Jul 14, 2026Truist SecuritiesMaintainedHold$205 → $250
Jul 10, 2026UBSMaintainedBuy$235 → $270
Jul 9, 2026BarclaysMaintainedEqual-Weight$194 → $218
May 11, 2026TD CowenMaintainedHold$144 → $201
May 8, 2026Truist SecuritiesMaintainedHold$158 → $205
May 8, 2026BarclaysMaintainedEqual-Weight$158 → $194
May 7, 2026UBSMaintainedBuy$190 → $235
May 6, 2026Deutsche BankUpgradeHold → Buy$126 → $220
Feb 4, 2026UBSMaintainedBuy$186 → $190

Peers & ETF holders

DVA peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On Oct. 9, DaVita HealthCare’s shares ended at $179.25, rising 1.26% and outperforming the S&P 500’s 0.6% gain. The firm’s next quarterly EPS is forecast at $3.78, a 50.6% increase from the prior year, with revenue projected at $3.53 billion, up 3.23% YoY. Analysts expect full‑year earnings of $14.57 per share and revenue of $14.28 billion, representing gains of 35.16% and 4.67% respectively. The data signals a solid earnings trajectory for the dialysis provider.
What did this article say?
DaVita Inc. (DVA) has seen its share price recover after a 25% decline, with analysts noting that the company’s aggressive share repurchase program is now more accretive due to lower valuation multiples. The firm trades at 9.4x forward earnings, making buybacks a more effective capital allocation tool than at recent highs. Despite flat industry volumes and Medicare rate headwinds, the buyback strategy is expected to drive EPS growth and enhance per‑share value. Key risks include the upcoming Medicare rate decision, high leverage, and volatile earnings reactions, suggesting cautious position sizing. Overall, the consensus remains a Buy rating with a $220 12‑month price target, implying a 22% upside from current levels.
What did this article say?
DaVita Inc. reported robust first‑quarter 2026 earnings, surpassing consensus in three of the last four quarters and driving a 55.8% year‑to‑date rally. The company raised its full‑year guidance, projecting 26.5% growth over the next five years, largely supported by its Integrated Kidney Care platform. Despite competitive pressures, payer‑mix challenges, and regulatory uncertainty, the market views the company’s execution and technology investments as a solid growth catalyst.
What did this article say?
DaVita activated its emergency response plan on Oct. 8 as Hurricane Isaias threatened the Gulf Coast and southeastern United States. The company urged kidney patients to confirm treatment schedules, prepare emergency supplies, and contact DaVita for assistance. DaVita’s teams coordinated with local care centers, healthcare partners, and emergency agencies to ensure uninterrupted dialysis services and safe operations. The plan included adjusting schedules, stocking extra supplies, and routing patients to alternate centers if closures occurred. The announcement reflected routine preparedness measures rather than a material operational change.
What did this article say?
DaVita HealthCare closed the day at $178.69, up 1.33% on a backdrop of broader market gains. The company’s stock outperformed the S&P 500 and lagged the Medical sector’s decline. Analysts anticipate earnings of $3.78 per share for the upcoming quarter, a 50.6% year‑over‑year increase, and a fiscal year EPS estimate of $14.57. Revenue guidance for the year is projected at $14.28 billion, up 4.67% from the prior year. The positive outlook is expected to support the stock’s recent upward momentum.
What did this article say?
The article evaluates cash‑producing companies, noting that not all cash‑rich firms are attractive investments. DaVita (DVA) is mentioned among the firms examined, with its free cash flow and growth metrics discussed in the context of broader industry trends. Overall, the review presents a balanced view, suggesting that DVA’s cash position is neither a definitive advantage nor a clear drawback.
What did this article say?
DaVita’s share price has risen 87.2% over the past three years, prompting analysts to assess whether the current valuation reflects the company’s earnings strength. The dialysis operator’s business model relies on recurring treatment volumes and disciplined cost control, which support consistent profit generation. Analysts have modeled the stock’s intrinsic value and concluded that the current price may still be justified by earnings, indicating potential upside if the market reconsiders its valuation. The analysis compares DaVita to a curated list of high-quality undervalued stocks, suggesting that investors may find the share price attractive relative to earnings fundamentals.
What did this article say?
Berkshire Hathaway reduced its stake in DaVita, selling between 1.2 and 1.6 million shares per quarter in 2026 after the dialysis company’s shares surged more than 58% year‑to‑date. The sale followed a peak holding of over 38 million shares in 2020, indicating a profit‑taking strategy. The move reflects Berkshire’s typical short‑term approach to healthcare investments and suggests a potential shift in its portfolio allocation.
What did this article say?
DaVita HealthCare (DVA) closed the trading day at $174.67, declining 4.62% from the prior close, while the S&P 500 slipped 0.03%. The company’s stock has risen 1.72% over the past month, outperforming the broader medical sector’s 4.15% loss. Analysts anticipate earnings of $3.78 per share for the upcoming quarter, representing a 50.6% year‑over‑year increase, and forecast fiscal‑year earnings of $14.57 per share. Investors will monitor the company’s earnings release for further guidance.
What did this article say?
DaVita (DVA) reported flat treatment volumes over the past two years, indicating a slowdown in demand for its dialysis services. The company has relied on price increases to maintain revenue, but this strategy has not translated into higher sales growth, which is projected at only 2% for the next year. Adjusted operating margin remained unchanged, suggesting limited improvement in cost leverage. These factors raise concerns about DVA’s ability to sustain profitability and support future growth.

Technical Analysis

Real-time indicators across multiple timeframes

59
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $9.39B combined position · 12 adding, 13 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Berkshire Hathaway Inc▼ Sell28,880,20945.31%$6.43B2026-08-14
BlackRock, Inc.▼ Sell2,460,9873.86%$547.52M2026-08-07
Vanguard Group Inc▼ Sell4,154,3546.52%$471.98M2026-01-29
Morgan Stanley▼ Sell1,601,7102.51%$356.35M2026-08-13
Invesco Ltd.▼ Sell1,211,9171.90%$269.63M2026-08-14
Neuberger Berman Group LLC▲ Buy925,5791.45%$205.76M2026-08-13
Geode Capital Management, LLC▼ Sell853,6021.34%$189.56M2026-08-12
Bank of America Corp▲ Buy651,9991.02%$145.06M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy640,8271.01%$142.57M2026-08-14
AQR Capital Management LLC▲ Buy587,7580.92%$128.13M2026-08-14
Goldman Sachs Group Inc▲ Buy463,3810.73%$103.09M2026-08-14
Northern Trust Corp▼ Sell382,0370.60%$85.00M2026-08-13
Norges Bank▼ Sell344,4220.54%$76.63M2026-08-12
JPMorgan Chase & Co▼ Sell200,7810.32%$44.47M2026-08-12
Citadel Advisors LLC▼ Sell199,8620.31%$44.47M2026-09-02
Gotham Asset Management, LLC▼ Sell163,5800.26%$36.39M2026-08-14
FMR LLC (Fidelity)▲ Buy114,5070.18%$25.48M2026-08-13
Davidson Kempner Capital Management LP▲ Buy113,0980.18%$25.16M2026-08-14
Millennium Management LLC▲ Buy77,0940.12%$17.15M2026-08-14
Verition Fund Management LLC▲ Buy43,7800.07%$9.74M2026-08-14
Brevan Howard Capital Management LP▲ Buy37,5000.06%$8.34M2026-08-14
Marshall Wace, LLP▲ Buy36,8970.06%$8.21M2026-08-13
Wells Fargo & Company▲ Buy29,4860.05%$6.56M2026-08-14
Susquehanna International Group, LLP▼ Sell28,7990.05%$6.41M2026-08-14
Citigroup Inc▼ Sell28,6100.04%$6.37M2026-08-03
Q2 2026 flow:1.43M sh bought ($316.81M)2.68M sh sold ($595.34M)net -1.25M sh (−$278.52M)
Congressional Trading Activity
9 disclosed trades · ~$72.0K est. traded value · 3 buys, 6 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-252025-10-07
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-09-232026-08-05
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-232026-08-05
Jerry MoranSenate-▼ Sell$1K - $15K2023-12-142024-01-17
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-12-122024-01-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-06-122023-07-14
Jerry MoranSenate-▼ Sell$1K - $15K2021-12-212022-01-21
Jerry MoranSenate-▲ Buy$1K - $15K2018-12-062019-05-15